MetaVia Secures $8.1 Million Funding for Obesity Treatment Development and Clinical Trials

MetaVia Secures Funding for Cardiometabolic Innovations

MetaVia Inc., a biotechnology firm located in Cambridge, Massachusetts, focuses on addressing cardiometabolic diseases. The company recently announces the pricing of its underwritten public offering, which aims to raise approximately $8.1 million before expenses. This funding is critical as it will support the ongoing clinical development of its promising treatment for obesity, DA-1726. The offering includes 2,613,544 shares of common stock, accompanied by Series C and Series D Warrants. These warrants are immediately exercisable at a price of $3.10 and represent a strategic financial vehicle for the company, allowing potential gross proceeds of up to $24 million if fully exercised.

The Series C Warrants are set to expire in five years, while the Series D Warrants will remain valid for two years but can be called upon following a successful data release from MetaVia's Phase 1b Part III clinical trial for DA-1726. This clinical trial is pivotal as it explores the efficacy of the treatment in addressing obesity, a significant contributor to various cardiometabolic disorders. The positive results from this trial are crucial not only for the company’s future but also for the larger healthcare landscape, where innovative solutions to obesity are urgently needed.

MetaVia plans to allocate the net proceeds from this offering toward working capital and the continued clinical development of DA-1726. By advancing its research and development efforts, MetaVia positions itself to potentially make a meaningful impact on the treatment of obesity and related conditions. With Ladenburg Thalmann & Co. Inc. acting as the sole book-running manager, the company is set to close the offering around January 16, 2026, pending customary closing conditions. This strategic move underscores MetaVia’s commitment to driving innovation within the cardiometabolic space.

In addition to the public offering, MetaVia has provided underwriters with a 45-day option to purchase additional shares and warrants at the public offering price. This flexibility may enhance the company's financial position and support its ambitious goals in clinical research. The securities offered are registered under a statement filed with the U.S. Securities and Exchange Commission, reflecting the company’s compliance with regulatory standards as it seeks to secure its future in the dynamic biotechnology industry.